Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01631968
Other study ID # ERITR-COL
Secondary ID
Status Completed
Phase N/A
First received June 28, 2012
Last updated February 23, 2016
Start date September 2007
Est. completion date May 2012

Study information

Verified date June 2012
Source Parc de Salut Mar
Contact n/a
Is FDA regulated No
Health authority Spain: Comité Ético de Investigación Clínica
Study type Interventional

Clinical Trial Summary

Prospective randomized study in cemented primary total knee arthroplasty. In one group the cement used was standard cement, without any antibiotics and in the other group the cement used was loaded with 0.5 g of erythromycin and 3 million units of colistin in 40 g of cement. In all cases intravenous antibiotics prophylaxis against infection was used. In both groups the cement was mechanically mixed in a vacuum. One deep drain tube was placed for 24 hours in all cases. The main variable was the presence of infection according to the Center of Disease Control criteria with a minimum of 12 months follow-up.


Recruitment information / eligibility

Status Completed
Enrollment 2948
Est. completion date May 2012
Est. primary completion date March 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Primary total knee replacement. Both genders. No age limits.

Exclusion Criteria:

- Allergy to erythromycin or colistin. Previous infection in the knee.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Infection
  • Infection After Primary Total Knee Arthroplasty

Intervention

Procedure:
Cement without antibiotic.

Cement with erytromycin and colistin.


Locations

Country Name City State
Spain Hospital de la Esperanza. Barcelona

Sponsors (1)

Lead Sponsor Collaborator
Parc de Salut Mar

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Infection Presence or absence of infection, according to the Center for Disease Control's criteria. The infection cases are classified as superficial of deep infection. The minimum follow-up is 12 months. No